Nanobiotechnology Laboratory, Biology Department, Faculty of Science, Razi University, Kermanshah, Iran.
Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Nanomedicine (Lond). 2020 Oct;15(24):2399-2410. doi: 10.2217/nnm-2020-0199. Epub 2020 Sep 18.
Nephrotoxicity, neurotoxicity and multidrug resistance in tumor cells can result from platinum-based anticancer (PBA) agents which can be reduced by nano formulations. Recently, novel formulations based on liposomes and cubosomes have been described as efficient strategies to overcome nephrotoxicity, ototoxicity, neurotoxicity, cardiotoxicity, hematological toxicities, hepatotoxicity and gastrointestinal toxicity as well as multidrug resistance. The co-delivery of anticancer agents concomitant with PBAs via biocompatible and biodegradable smart liposomes and cubosomes can augment therapeutic results of chemotherapy as well as radiotherapy owing to their high accessibility of surface and internal modification. For this purpose, surface, bilayer or core sections of these formulations can be functionalized by pure PBAs or modified PBAs. In this review, recent significant advances and challenges related to various liposomal and cubosomal formulations of PBA are presented in order to emphasize suitable formulations for anticancer applications with critical thoughts provided on how the field can progress.
肾毒性、神经毒性和肿瘤细胞的多药耐药性可能源于基于铂的抗癌（PBA）药物，纳米制剂可以减少这些药物的副作用。最近，基于脂质体和立方脂质体的新型制剂被描述为克服肾毒性、耳毒性、神经毒性、心脏毒性、血液毒性、肝毒性和胃肠道毒性以及多药耐药性的有效策略。通过生物相容性和可生物降解的智能脂质体和立方脂质体共递抗癌药物和 PBA 可以增强化疗和放疗的治疗效果，因为它们具有很高的表面和内部修饰的可及性。为此，这些制剂的表面、双层或核心部分可以通过纯 PBA 或修饰的 PBA 进行功能化。在这篇综述中，介绍了与各种 PBA 的脂质体和立方脂质体制剂相关的最新重要进展和挑战，以强调适合抗癌应用的合适制剂，并就该领域如何取得进展提出了批判性的思考。
